ERBB2 - erb-b2 receptor tyrosine kinase 2 Gene

Species: Sus scrofa

Gene Type: protein coding
Gene ID: 100516641

About ERBB2

Primary_assembly 12: 22,590,725-22,621,351 reverse strand.Sscrofa11.1:CM000823.5

This gene has 5 transcripts (splice variants), 200 orthologues and 52 paralogues. Broad expression in kidney (RPKM 31.9), ovary (RPKM 21.1) and 8 other tissues.

ERBB2 Products (1)

mRNA Protein Name
NM_001315613.1 NP_001302542.1 receptor tyrosine-protein kinase erbB-2 precursor

ERBB2 Protein Structure

Recep_L_domain

Recep_L_domain: pfam01030 (51 - 172)

Furin-like

Furin-like: pfam00757 (274 - 418)

Recep_L_domain

Recep_L_domain: pfam01030 (446 - 562)

GF_recep_IV

GF_recep_IV: pfam14843 (590 - 723)

TM_ErbB2

TM_ErbB2: cd12094 (721 - 764)

PTKc_HER2

PTKc_HER2: cd05109 (792 - 1070)

  • 0
  • 300
  • 600
  • 900
  • 1200
  • 1336 a.a.
Protein Preferred Names Protein Names

receptor tyrosine-protein kinase erbB-2

  • v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2

  • v-erb-b2 avian erythroblastic leukemia viral oncogene-like protein 2

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (6)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-50898 Lapatinib 99.83% Yes
HY-13272 Dacomitinib 99.74% Yes
HY-50898A Lapatinib ditosylate 99.98% Yes
HY-50898B Lapatinib ditosylate monohydrate 99.99% Yes
HY-16069A Tucatinib hemiethanolate Inhibitor 98.82% Yes
HY-50898C Lapatinib tosylate / Unkown

Clinical Phase

Bioactive Molecules (13)
Cat. No. Product Name Effect
Purity Phase
HY-13050 Sapitinib Inhibitor 99.93% Phase 2
HY-10367 Canertinib Inhibitor 99.74% Phase 2
HY-32718 Pelitinib Inhibitor 99.13% Phase 2
HY-10045 AEE788 98.39% Phase 2
HY-14674 CP-724714 98.72% Phase 2
HY-10367A Canertinib dihydrochloride Inhibitor 99.68% Phase 2
HY-13427 Allitinib tosylate Inhibitor 99.54% Phase 2
HY-10322 Falnidamol Inhibitor 99.41% Phase 1
HY-103443 HKI-357 Inhibitor 99.24% Phase 1
HY-116437 Selatinib Inhibitor 98.56% Phase 1
HY-10346 AV-412 Inhibitor 99.17% Phase 1
HY-135366 HPN-01 Inhibitor 98.61% Phase 1
HY-10346A AV-412 free base Inhibitor 98.10% Phase 1
Bioactive MoleculesInhibitory Antibodies (2)
Cat. No. Product Name Effect
Purity Phase
HY-P990697 Anvatabart Inhibitor 98.15% Phase 3
HY-P991524 MM-111 Inhibitor / Phase 2

Pre-clinical Phase

Bioactive Molecules (51)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-112411 PD 174265 98.35% Unkown
HY-13896 PD168393 98.01% Unkown
HY-18609 PD158780 Inhibitor 99.47% Unkown
HY-15375 Allitinib Inhibitor 98.88% Unkown
HY-20878 Tyrphostin AG 879 99.26% Unkown
HY-10325 CL-387785 99.31% Unkown
HY-15844 AG-825 98.13% Unkown
HY-P4082 ErbB-2-binding peptide 99.52% Unkown
HY-150023 BI-1622 Inhibitor 98.02% Unkown
HY-103440 EGFR/ErbB-2/ErbB-4 inhibitor-3 Inhibitor 96.78% Unkown
HY-123035 Gamendazole Inhibitor 99.44% Unkown
HY-101042 AG-494 Inhibitor 98.69% Unkown
HY-112420 EGFR/ErbB-2-IN-2 Inhibitor 99.45% Unkown
HY-103441 JNJ28871063 hydrochloride Inhibitor 98.36% Unkown
HY-50898S Lapatinib-d4 99.02% Unkown
HY-N1166 Tephrosin 98.02% Unkown
HY-RS04466 ERBB2 Human Pre-designed siRNA Set A / Unkown
HY-100499 Tyrphostin AG 528 Inhibitor 98.0% Unkown
HY-103439 GW583340 dihydrochloride Inhibitor / Unkown
HY-13272S2 Dacomitinib-d10 dihydrochloride ≥95.0% Unkown
HY-E70715 ERBB2 775YVMA776 Recombinant Human Active Protein Kinase / Unkown
HY-123726 ErbB-1/ErbB-2 tyrosine kinase-IN-1 / Unkown
HY-147407 Imbotolimod Inhibitor / Unkown
HY-103439A GW583340 Inhibitor / Unkown
HY-118900 CP-654577 / Unkown
HY-129288 GW837016X Inhibitor / Unkown
HY-13050A Sapitinib fumarate Inhibitor / Unkown
HY-13272S3 Dacomitinib-d10 / Unkown
HY-137028 2′-Thioadenosine Inhibitor / Unkown
HY-156639 EGFR/ErbB-2 inhibitor-1 Inhibitor / Unkown
HY-168577 KRAS G12D inhibitor 25 / Unkown
HY-175809 SRT6 Inhibitor / Unkown
HY-177989 ER121 Inhibitor 98.52% Unkown
HY-50898S1 Lapatinib-d7 dihydrochloride / Unkown
HY-50898S2 Lapatinib-d5 / Unkown
HY-50898S3 Lapatinib-d4-1 / Unkown
HY-50898S5 Lapatinib-13C,d7 / Unkown
HY-P10981 ErbB2 peptide Ligand / Unkown
HY-RS04467 Erbb2 Mouse Pre-designed siRNA Set A / Unkown
HY-RS04468 ERBB2 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W008914 (E/Z)-CP-724714 Inhibitor / Unkown
HY-W740576 7-Descarbamoyl-17-amino geldanamycin / Unkown
HY-W777297 Lapatinib-13C2,15N Ditosylate / Unkown
HY-10325R CL-387785 (Standard) / Unkown
HY-103443A HKI-357 dimaleate Inhibitor / Unkown
HY-160068 2-2(t) aptamer sodium Chemical 99.28% Unkown
HY-174671 Human HBEGF mRNA / Unkown
HY-178740 GI261520A Inhibitor / Unkown
HY-32718S Pelitinib-d6 / Unkown
HY-50898CS Lapatinib-d4 tosylate / Unkown
HY-50898S4 Lapatinib-d7 / Unkown
Bioactive MoleculesInhibitory Antibodies (8)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P99558 Timigutuzumab Inhibitor 97.53% Unkown
HY-P990909 Calotatug 98% Unkown
HY-P990978 Caxmotabart 96.56% Unkown
HY-P990695 Lunaxafusp Inhibitor / Unkown
HY-P990972 Azerutamig / Unkown
HY-P992107 Dulpatatug Inhibitor 99.09% Unkown
HY-P991243 MP-RM-1 Inhibitor 96.29% Unkown
HY-P991979 Erbicin Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens ERBB2 NCBI NCBI:2064